The Impact of Preexisting and Post-transplant Diabetes Mellitus on Outcomes Following Liver Transplantation

被引:38
作者
Aravinthan, Aloysious D. [1 ,2 ,3 ,4 ]
Fateen, Waleed [2 ,3 ,4 ]
Doyle, Adam C. [1 ,5 ]
Venkatachalapathy, Suresh V. [3 ,4 ]
Lssachar, Assaf [1 ,6 ]
Galvin, Zita [1 ]
Sapisochin, Gonzalo [1 ]
Cattral, Mark S. [1 ]
Ghanekar, Anand [1 ]
McGilvray, Ian D. [1 ]
Selzner, Markus [1 ]
Grant, David R. [1 ]
Selzner, Nazia [1 ]
Lilly, Leslie B. [1 ]
Renner, Eberhard L. [1 ,7 ]
Bhat, Mamatha [1 ]
机构
[1] Univ Toronto, Toronto Gen Hosp, Multiorgan Transplant Program, Toronto, ON, Canada
[2] Univ Nottingham, Nottingham Digest Dis Ctr, Sch Med, Nottingham, England
[3] Nottingham Univ Hosp NHS Trust, Nottingham Biomed Res Ctr, NIHR, Nottingham, England
[4] Univ Nottingham, Nottingham, England
[5] Royal Perth Hosp, Dept Gastroenterol & Hepatol, Perth, Australia
[6] Beilinson Med Ctr, Liver Inst, Rabin Med Ctr, Petah Tiqwa, Israel
[7] Univ Manitoba, Dept Med, Max Rady Coll Med, Rady Fac Hlth Sci, Winnipeg, MB, Canada
关键词
RISK-FACTORS; RECIPIENTS; GRAFT; SURVIVAL; PATIENT;
D O I
10.1097/TP.0000000000002757
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Diabetes mellitus (DM) is said to adversely affect transplant outcomes. The aim of this study was to investigate the impact of pre-existing and new-onset DM on liver transplantation (LT) recipients. Methods. A single-center retrospective analysis of prospectively collected data of LT recipients (1990-2015) was undertaken. Results. Of the 2209 patients, 13% (n = 298) had Pre-DM, 16% (n = 362) developed post-transplant diabetes mellitus (PTDM), 5% (n = 118) developed transient hyperglycemia (t-HG) post-LT, and 65% (n = 1431) never developed DM (no DM). Baseline clinical characteristics of patients with PTDM were similar to that of patients with Pre-DM. Incidence of PTDM peaked during the first year (87%) and plateaued thereafter. On multivariate analysis (Bonferroni-corrected), nonalcoholic fatty liver disease and the use of tacrolimus and sirolimus were independently associated with PTDM development. Both Pre-DM and PTDM patients had satisfactory and comparable glycemic control throughout the follow-up period. Those who developed t-HG seem to have a unique characteristic compared with others. Overall, 9%, 5%, and 8% of patients developed end-stage renal disease (ESRD), major cardiovascular event (mCVE), and de novo cancer, respectively. Both Pre-DM and PTDM did not adversely affect patient survival, retransplantation, or de novo cancer. The risks of ESRD and mCVE were significantly higher in patients with Pre-DM followed by PTDM and no DM. Conclusions. In this largest nonregistry study, patients with Pre-DM and PTDM share similar baseline clinical characteristics. Pre-DM increases the risk of ESRD and mCVE; however, patient survival was comparable to those with PTDM and without diabetes. Understanding the impact of PTDM would need prolonged follow-up.
引用
收藏
页码:2523 / 2530
页数:8
相关论文
共 44 条
[1]   Risk Factors for Development of New-Onset Diabetes Mellitus and Progressive Impairment of Glucose Metabolism After Living-Donor Liver Transplantation [J].
Abe, T. ;
Onoe, T. ;
Tahara, H. ;
Tashiro, H. ;
Ishiyama, K. ;
Ide, K. ;
Ohira, M. ;
Ohdan, H. .
TRANSPLANTATION PROCEEDINGS, 2014, 46 (03) :865-869
[2]   Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR) [J].
Adam, Rene ;
Karam, Vincent ;
Delvart, Valerie ;
O'Grady, John ;
Mirza, Darius ;
Klempnauer, Jurgen ;
Castaing, Denis ;
Neuhaus, Peter ;
Jamieson, Neville ;
Salizzoni, Mauro ;
Pollard, Stephen ;
Lerut, Jan ;
Paul, Andreas ;
Carlos Garcia-Valdecasas, Juan ;
Juan Rodriguez, Fernando San ;
Burroughs, Andrew .
JOURNAL OF HEPATOLOGY, 2012, 57 (03) :675-688
[3]  
Alagbe SC, 2017, SAMJ S AFR MED J, V107, P791, DOI [10.7196/SAMJ.2017.v107i9.12258, 10.7196/samj.2017.v107i9.12258]
[4]   New-Onset Diabetes and Preexisting Diabetes Are Associated With Comparable Reduction in Long-Term Survival After Liver Transplant: A Machine Learning Approach [J].
Bhat, Venkat ;
Tazari, Mahmood ;
Watt, Kymberly D. ;
Bhat, Mamatha .
MAYO CLINIC PROCEEDINGS, 2018, 93 (12) :1794-1802
[5]   New-onset diabetes mellitus in the kidney recipient: Diagnosis and management strategies [J].
Bloom, Roy D. ;
Crutchlow, Michael F. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 :S38-S48
[6]   The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells [J].
Bussiere, C. T. ;
Lakey, J. R. T. ;
Shapiro, A. M. J. ;
Korbutt, G. S. .
DIABETOLOGIA, 2006, 49 (10) :2341-2349
[7]   Pretransplant Fasting Glucose Predicts New-Onset Diabetes after Liver Transplantation [J].
Carey, Elizabeth J. ;
Aqel, Bashar A. ;
Byrne, Thomas J. ;
Douglas, David D. ;
Rakela, Jorge ;
Vargas, Hugo E. ;
Moss, Adyr A. ;
Mulligan, David C. ;
Reddy, K. Sudhakar ;
Chakkera, Harini A. .
JOURNAL OF TRANSPLANTATION, 2012, 2012
[8]   Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels [J].
Cho, Yongin ;
Lee, Min Jung ;
Choe, Eun Yeong ;
Jung, Chang Hee ;
Joo, Dong Jin ;
Kim, Myoung Soo ;
Cha, Bong Soo ;
Park, Joong-Yeol ;
Kang, Eun Seok .
LIVER TRANSPLANTATION, 2014, 20 (05) :557-563
[9]   New-Onset Diabetes After Transplantation: Assessment of Risk Factors and Clinical Outcomes [J].
Cotovio, P. ;
Neves, M. ;
Rodrigues, L. ;
Alves, R. ;
Bastos, M. ;
Baptista, C. ;
Macario, F. ;
Mota, A. .
TRANSPLANTATION PROCEEDINGS, 2013, 45 (03) :1079-1083
[10]   New-onset diabetes after transplantation: 2003 International Consensus Guidelines [J].
Davidson, J ;
Wilkinson, A ;
Dantal, J ;
Dotta, F ;
Haller, H ;
Hernández, D ;
Kasiske, BL ;
Kiberd, B ;
Krentz, A ;
Legendre, C ;
Marchetti, P ;
Markell, M ;
van der Woude, FJ ;
Wheeler, DC .
TRANSPLANTATION, 2003, 75 (10) :SS3-SS24